CA2383254A1 - Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci - Google Patents

Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci Download PDF

Info

Publication number
CA2383254A1
CA2383254A1 CA002383254A CA2383254A CA2383254A1 CA 2383254 A1 CA2383254 A1 CA 2383254A1 CA 002383254 A CA002383254 A CA 002383254A CA 2383254 A CA2383254 A CA 2383254A CA 2383254 A1 CA2383254 A1 CA 2383254A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
cell
sequence identity
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383254A
Other languages
English (en)
Inventor
Avi J. Ashkenazi
Kevin P. Baker
David Botstein
Luc Desnoyers
Dan L. Eaton
Napoleone Ferrara
Sherman Fong
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
J. Christopher Grimaldi
Austin L. Gurney
Ivar J. Kljavin
Mary A. Napier
James Pan
Nicholas F. Paoni
Margaret Ann Roy
Timothy A. Stewart
Daniel Tumas
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/fr
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/fr
Priority claimed from PCT/US1999/030911 external-priority patent/WO2000075316A1/fr
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/fr
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/fr
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Priority claimed from PCT/US2000/005004 external-priority patent/WO2000053757A2/fr
Priority claimed from PCT/US2000/004914 external-priority patent/WO2000075327A1/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/007377 external-priority patent/WO2001019991A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2383254A1 publication Critical patent/CA2383254A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)

Abstract

La présente invention concerne des polypeptides et des molécules d'acides nucléiques codant pour ces polypeptides. Cette invention concerne aussi des vecteurs et des cellules hôtes qui comprennent ces séquences d'acides nucléiques, des molécules de polypeptides chimériques qui comprennent les polypeptides de l'invention fusionnés avec les séquences de polypeptides hétérologues, des anticorps se liant aux polypeptides de l'invention et des techniques permettant d'obtenir les polypeptides de l'invention.
CA002383254A 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci Abandoned CA2383254A1 (fr)

Applications Claiming Priority (49)

Application Number Priority Date Filing Date Title
PCT/US1999/012252 WO1999063088A2 (fr) 1998-06-02 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
USPCT/US99/12252 1999-06-02
US14103799P 1999-06-23 1999-06-23
US60/141,037 1999-06-23
US14304899P 1999-07-07 1999-07-07
US60/143,048 1999-07-07
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
US14622299P 1999-07-28 1999-07-28
US60/146,222 1999-07-28
US14939699P 1999-08-17 1999-08-17
US60/149,396 1999-08-17
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
USPCT/US99/21547 1999-09-15
USPCT/US99/21090 1999-09-15
US15866399P 1999-10-08 1999-10-08
US60/158,663 1999-10-08
USPCT/US99/28313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
USPCT/US99/28301 1999-12-01
PCT/US1999/028301 WO2000032776A2 (fr) 1998-12-01 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
PCT/US1999/030095 WO2000037640A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
USPCT/US99/30095 1999-12-16
PCT/US1999/030911 WO2000075316A1 (fr) 1999-06-02 1999-12-20 Procedes et compositions pour l'inhibition de la croissance de cellules neoplastiques
USPCT/US99/30911 1999-12-20
PCT/US2000/000219 WO2000053753A2 (fr) 1999-03-08 2000-01-05 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/00219 2000-01-05
USPCT/US00/00376 2000-01-06
PCT/US2000/000376 WO2000053755A2 (fr) 1999-03-08 2000-01-06 Compositions et procedes pour le traitement de tumeur
USPCT/US00/03565 2000-02-11
PCT/US2000/003565 WO2001053486A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
USPCT/US00/04341 2000-02-18
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/04414 2000-02-22
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04914 2000-02-24
USPCT/US00/05004 2000-02-24
PCT/US2000/005004 WO2000053757A2 (fr) 1999-03-08 2000-02-24 Activation et inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/004914 WO2000075327A1 (fr) 1999-06-02 2000-02-24 Methodes et compositions d'inhibition de croissance cellulaire neoplasique
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
USPCT/US00/05841 2000-03-02
USPCT/US00/06884 2000-03-15
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
USPCT/US00/07377 2000-03-20
PCT/US2000/007377 WO2001019991A1 (fr) 1999-09-15 2000-03-20 Compositions et techniques permettant de traiter des maladies d'origine immunologique
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci

Publications (1)

Publication Number Publication Date
CA2383254A1 true CA2383254A1 (fr) 2000-12-07

Family

ID=42676646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383254A Abandoned CA2383254A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci

Country Status (6)

Country Link
EP (1) EP1210418B1 (fr)
JP (4) JP2004522402A (fr)
AT (1) ATE478145T1 (fr)
AU (1) AU3774300A (fr)
CA (1) CA2383254A1 (fr)
WO (1) WO2000073454A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
CA2301796A1 (fr) 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 proteines secretees humaines
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU764441B2 (en) 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1109937B1 (fr) 1998-09-02 2008-11-05 Diadexus, Inc. PROCEDE DE DIAGNOSTIC, DE SURVEILLANCE, DE CLASSIFICATION PAR STADES et D'IMAGERIE DE DIVERS CANCERS
CA2341326A1 (fr) * 1998-09-03 2000-03-16 Takeda Chemical Industries, Ltd. Nouvelle proteine et son procede de production
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2007216683B2 (en) * 1998-12-17 2011-07-14 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
CA2356987A1 (fr) * 1998-12-23 2000-06-29 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2380355A1 (fr) * 1999-09-01 2001-03-08 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
EP1623991A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP1220919A2 (fr) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts C4.4a, antigene associee a la metastase
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
JP4741139B2 (ja) * 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1244784A2 (fr) * 2000-01-06 2002-10-02 Genentech, Inc. Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
EP1947182A1 (fr) * 2000-02-15 2008-07-23 Amgen Inc. Molécules 23 à facteur de croissance de fibroblaste et utilisations associées
CA2398603A1 (fr) * 2000-02-15 2001-08-23 Amgen, Inc. Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
AU2001245371A1 (en) 2000-02-28 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
US20020082205A1 (en) * 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
CA2407746A1 (fr) * 2000-05-04 2001-11-08 Incyte Genomics, Inc. Proteases
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
WO2001087933A2 (fr) * 2000-05-11 2001-11-22 Zymogenetics, Inc. Peptides de type zsig33
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
EP1294885A2 (fr) * 2000-06-30 2003-03-26 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
WO2002006483A1 (fr) * 2000-07-18 2002-01-24 Takeda Chemical Industries, Ltd. Nouveau peptide actif sur le plan physiologique et utilisation associee
AU7332301A (en) 2000-07-19 2002-02-05 Advanced Res & Tech Inst Novel fibroblast growth factor (FGF23) and methods for use
EP2233571B1 (fr) * 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Polypeptides de régulation du métabolisme de l'acide phosphorique, du métabolisme du calcium, du métabolisme de la calcification et de la vitamine D et des ADN codant pour de tels polypeptides
EP1341814A2 (fr) * 2000-09-01 2003-09-10 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
AU2002230778A1 (en) 2000-11-03 2002-05-15 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
CN1269960C (zh) * 2000-12-26 2006-08-16 中外制药株式会社 降低血磷水平的人fgf23蛋白质突变体
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
EP1881007A1 (fr) * 2001-03-27 2008-01-23 Novartis AG LLR-J24 polypeptides associées
US6734289B2 (en) * 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP1573024A4 (fr) 2001-04-10 2007-08-29 Agensys Inc Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
WO2003002737A1 (fr) * 2001-06-27 2003-01-09 Riken Nouvelle proteine inhibitrice de la topoisomerase humaine 2$g(a) et utilisation associee
IL159872A0 (en) * 2001-07-26 2004-06-20 Genset Sa Gmg-2 polypeptides and their use
KR101016476B1 (ko) 2001-12-28 2011-02-24 교와 핫꼬 기린 가부시키가이샤 섬유아세포 증식 인자-23에 대한 항체
AU2003215761A1 (en) * 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2002303430A1 (en) * 2002-04-23 2003-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003102194A1 (fr) * 2002-05-31 2003-12-11 Seikagaku Corporation Chondroitine synthetase et codage de l'adn pour l'enzyme
WO2004022087A1 (fr) * 2002-09-04 2004-03-18 Takeda Pharmaceutical Company Limited Utilisation d'un gene associe a une maladie
AU2003277616A1 (en) * 2002-11-07 2004-06-07 National Institute Of Advanced Industrial Science And Technology Method of detecting bone Paget' disease
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2004058044A2 (fr) 2002-11-19 2004-07-15 Drg International, Inc. Methode diagnostique pour maladies par criblage d'hepcidine dans des tissus, du sang ou des fluides corporels humains ou animaux et utilisations therapeutiques
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
EP2526960A1 (fr) 2003-03-12 2012-11-28 Genentech, Inc. Utilisation de BV8 et/ou de EG-VEGF pour promouvoir l'hématopoièse
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
ATE395430T1 (de) * 2003-05-28 2008-05-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit pils verbundenen krankheiten
JP4901478B2 (ja) * 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
AU2004308972C1 (en) * 2003-12-24 2009-11-26 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005068497A1 (fr) * 2004-01-06 2005-07-28 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Iis: nouvel proteine inductible par ifn-gamma, element de la famille des secretoglobines, modulant l'invasion et la migration cellulaire
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2006034189A (ja) * 2004-07-28 2006-02-09 National Institute Of Advanced Industrial & Technology 組織の癌化の検出方法
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
CN100460013C (zh) * 2006-09-05 2009-02-11 重庆康卫生物科技有限公司 口服重组幽门螺杆菌疫苗及其制备方法
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
TWI409276B (zh) 2007-11-02 2013-09-21 Lilly Co Eli 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
JP5730200B2 (ja) 2008-08-06 2015-06-03 イーライ リリー アンド カンパニー 抗ヘプシジン−２５選択的抗体およびその使用
CA2789061A1 (fr) 2010-02-26 2011-09-01 Henrik Parshad Compositions stables contenant des anticorps
CA2800188A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
EP3385277A1 (fr) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Polypeptides il-22 et protéines de fusion fc il-22 et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
EP0998490A2 (fr) * 1997-03-25 2000-05-10 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
WO1999006550A2 (fr) * 1997-08-01 1999-02-11 Genset Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate
DE19811194A1 (de) * 1998-03-10 1999-09-16 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Prostatagewebe
DE19817557A1 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
JPH11332571A (ja) * 1998-05-29 1999-12-07 Taisho Pharmaceut Co Ltd 新規遺伝子とそれにコードされる蛋白質
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
AU5730099A (en) * 1998-08-03 2000-02-28 Novartis Ag Novel genes in control of hematopoiesis
CA2296792A1 (fr) * 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
CA2362924A1 (fr) * 1999-03-01 2000-09-08 Millennium Pharmaceuticals, Inc. Proteines secretees et acides nucleiques codant pour elles
AU5151100A (en) * 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
EP1230362A2 (fr) * 1999-11-16 2002-08-14 ZymoGenetics, Inc. Proteines humaines zven
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
JP4017507B2 (ja) 2007-12-05
AU3774300A (en) 2000-12-18
JP2007302681A (ja) 2007-11-22
EP1210418B1 (fr) 2010-08-18
JP2011236224A (ja) 2011-11-24
JP5512073B2 (ja) 2014-06-04
ATE478145T1 (de) 2010-09-15
JP2004522402A (ja) 2004-07-29
JP2004203742A (ja) 2004-07-22
EP1210418A1 (fr) 2002-06-05
WO2000073454A1 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
CA2383254A1 (fr) Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
CA2328895A1 (fr) Proteines membranaires et acides nucleiques codant ces proteines
US7244816B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020137890A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030073090A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050112725A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU761340B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004516802A (ja) 膜結合タンパク質及びそれをコードする核酸
US20020137075A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050187382A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
ZA200006681B (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same.
MXPA00011932A (en) Membrane-bound proteins and nucleic acids encoding the same
EP1250437A2 (fr) Proteines membranaires et acides nucleiques codant ces proteines
JP2005304500A (ja) ポリペプチドを含有する医薬
KR20020095599A (ko) 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130715